Ten-Year Real-Life Experience With Varenicline in a Hospital-Based Smoking Cessation Program

Q4 Medicine

Open Respiratory Archives Pub Date : 2026-04-01 Epub Date: 2026-01-15 DOI:10.1016/j.opresp.2026.100582

Lucía Gimeno , Juan Rodríguez-López , Concepción Rodríguez-García , Lorena González-Justo , Manuel Ángel Martínez-Muñiz , Jesús Allende-González

引用次数: 0

Abstract

To assess the real-life efficacy and safety of varenicline in a hospital-based smoking cessation program.

We conducted a longitudinal prospective study including 310 smokers treated with varenicline at our hospital's Smoking Cessation Unit between 2011 and 2021.

Abstinence rates at 3, 6, and 12 months were 51.3%, 40.0%, and 36.5%, respectively. Smoking the first cigarette within 5 min of waking was independently associated with treatment failure (OR: 2.516, p = 0.02). Adverse events occurred in 27% of patients, leading to treatment discontinuation in 11%.

Varenicline demonstrated favorable efficacy and safety in real-world clinical practice, regardless of baseline motivation or comorbidities. Active follow-up is essential to optimize adherence and long-term success.

查看原文本刊更多论文

在医院戒烟项目中使用伐尼克兰十年的实际经验。

评估伐尼克兰在医院戒烟项目中的实际疗效和安全性。我们进行了一项纵向前瞻性研究，包括2011年至2021年间在我院戒烟部门接受varenicline治疗的310名吸烟者。3、6、12个月的戒断率分别为51.3%、40.0%、36.5%。醒来后5分钟内吸第一支烟与治疗失败独立相关（OR: 2.516, p = 0.02）。27%的患者发生不良事件，11%的患者停止治疗。在现实世界的临床实践中，无论基线动机或合并症如何，伐尼克兰都显示出良好的疗效和安全性。积极的随访对于优化依从性和长期成功至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊